Niall Martin is on a mission to put DNA repair on the map. He has already gone pretty far along the way to doing this, as the leader of the team that developed the blockbuster cancer drug Lynparza. He is now seeking to repeat this early success at Artios, where he is CEO. Martin talked […]
Click this link to register and listen to the insightful podcast from Verona Pharma’s Investor and Analyst R&D Day forum 2019
Continuing Cambridge’s tradition as a centre of excellence for DNA Damage Response with leading next generation programmes.
Arix Bioscience (ARIX) CEO Joe Anderson talked to VoxMarkets about investing in and building breakthrough biotech companies to market.
Only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK
